NASDAQ
2.90USD
-0.17 (-5.54%)
We have scored 7 news catalysts on Prime Medicine, Inc. (PRME) over the past 12 months. The biggest single-day move next to one of them came Nov 11, 2025, when PRME closed +11.0%: “Prime Medicine to Present at Jefferies Global Healthcare Conference”. Coverage across the window leans positive (average ticker sentiment +0.50). Most of the impact sits in short squeeze potential and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
523.8M
P/E
—
EPS
—
Beta
2.35
52W range
2.67-6.94
Day range
2.88–3.44
Open
3.42
Prev close
3.07
Volume
7.1M
Avg volume
3.2M
Dividend
0.00
IPO
2022-10-20
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Prime Medicine, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PRME: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
